Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer-Reference-Cited by-同舟云学术

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancer

Published:2021-01-09 Issue:5 Volume:60 Page:373-384
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosomes Cancer

Author:

Singh Hans Martin¹,Bailey Peter²³,Hübschmann Daniel⁴⁵⁶⁷^ORCID,Berger Anne Katrin¹,Neoptolemos John P.³,Jäger Dirk¹,Siveke Jens⁸⁹,Springfeld Christoph¹^ORCID

Affiliation:

1. Department of Medical Oncology, Heidelberg University Hospital National Center for Tumor Diseases Heidelberg Germany

2. Institute of Cancer Sciences University of Glasgow Glasgow UK

3. Department of Surgery Heidelberg University Hospital Heidelberg Germany

4. Computational Oncology, Molecular Diagnostics Program National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ) Heidelberg Germany

5. Heidelberg Institute for Stem cell Technology and Experimental Medicine (HI‐STEM) Heidelberg Germany

6. German Cancer Consortium (DKTK) Heidelberg Germany

7. Department of Pediatric Immunology, Hematology and Oncology Heidelberg University Hospital Heidelberg Germany

8. Institute for Developmental Cancer Therapeutics, West German Cancer Center University Medicine Essen Essen Germany

9. Division of Solid Tumor Translational Oncology German Cancer Consortium (DKTK, partner site University Hospital Essen) and German Cancer Research Center (DKFZ) Heidelberg Germany

Publisher

Wiley

Subject

Cancer Research,Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/gcc.22932

Reference83 articles.

1. Pancreatic cancer

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study

4. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

5. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families;Journal of Personalized Medicine;2024-08-16

2. Comprehensive characterization of B7 family members in breast cancer: B7-H5 switch reverses breast cancer from “immuno-cold” into “immuno-hot” status;Cancer Cell International;2024-06-10

3. Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma;Cancers;2024-05-31

4. Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?;Critical Reviews in Oncology/Hematology;2023-10

5. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial;The Oncologist;2023-06-20